Navigation Links
CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
Date:10/7/2008

VIENNA, Va., Oct. 7 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE: CVM) announced today that it has entered into a Material Transfer Agreement (MTA) with the National Institutes of Health Clinical Center (NIHCC) and the laboratory of Dr. Francesco M. Marincola, M.D., to investigate the molecular basis of changes to the tumor microenvironment caused by CEL-SCI's cancer drug Multikine. Dr. Marincola is the Chief of the Infectious Disease and Immunogentics Section, Department of Transfusion Medicine Clinical Center, National Institutes of Health, a leading national and international medical research laboratory.

Pursuant to the agreement, CEL-SCI will provide tumor samples of Multikine treated and untreated matched control patients to the NIHCC, which will then use the latest molecular genomic microarray technology developed by Dr. Marincola's laboratory to look for molecular genomic differences in the tumor microenvironment in patients with squamous cell carcinoma of the head and neck. Should these pre-clinical experiments find significant differences between the Multikine treated and untreated patients, a formal collaboration between CEL-SCI and the NIHCC may be developed in order to expand the study to include patients from CEL-SCI's Pivotal global Phase III clinical trial.

"Multikine's potential to change the tumor microenvironment and, in doing so, break tumor tolerance has been a long-time goal of anti-cancer immunotherapy. We are very excited to be working with Dr. Marincola and the NIH Clinical Center to determine the molecular basis of Multikine's ability to cause tumor microenvironment changes," said Dr. Talor, Senior VP of Research and Manufacturing at CEL-SCI and the developer of Multikine.

About CEL-SCI's Phase III Cancer Drug Multikine:

CEL-SCI is developing Multikine for approval as a first-line indication in head and neck cancer. The company's upcoming Pivotal global Phase III clinical trial is an 800 patient study designed to demonstrate that administration of its anti-cancer drug Multikine to head and neck cancer patients before they receive their first conventional cancer treatment will increase their survival. Head and neck cancer is one of the world's biggest cancers affecting about 650,000 people per annum.

In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine for the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck, in May 2007. In the summer of 2007 CEL-SCI started construction of the manufacturing facility to produce Multikine for the global Phase III trial and subsequent sale following approval. This facility is expected to be completed soon.

Multikine, a patented defined mixture of naturally derived cytokines is the first immunotherapeutic agent in a new class of drugs called "Immune SIMULATORS." Immune SIMULATORS simulate the way our natural immune system acts in defending us against cancer. As opposed to other immunotherapies which are designed to target a single or limited number of specific antigens or molecules, Immune SIMULATORS are multi-targeted; they simultaneously cause a direct and targeted killing of the specific tumor cells and they activate the immune system to produce a stronger anti-tumor attack on multiple fronts.

Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. It is administered prior to any other cancer therapy because that is the period when the anti-tumor immune response can still be fully activated. Once the patient has advanced disease, or had surgery or has received radiation and/or chemotherapy, the immune system is severely weakened and is less able to mount an effective anti-tumor immune response. Other immunotherapies are administered after the patient has received chemotherapy and/or radiation therapy, which can limit their effectiveness.

The Company has operations in Vienna, Virginia and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense.

NO ENDORSEMENT OF ANY ORGANIZATION, PRODUCT OR SERVICE MENTIONED IN THIS ARTICLE IS INTENDED OR INFERRED BY THE NATIONAL INSTITUTES OF HEALTH OR ITS EMPLOYEES.


'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
2. CEL-SCI Corporation Releases Letter to Shareholders
3. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
4. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
5. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
6. CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
8. CEL-SCI Corporation Announces 2007 Financial Results
9. CEL-SCI Corporation Reports First Quarter Financial Results
10. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
11. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... 2017 AccuGenomics, Inc., a diagnostic company based ... that the company has provided an AccuKit to the ... at Chapel Hill and to Qura Therapeutics for evaluation ... quantify HIV reservoir and viral expression in human CD4+ ... Cure Center is a joint initiative between the University ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... Inc. (NYSE: DPLO), the nation,s largest independent specialty pharmacy, announced ... comparisons, unless otherwise noted, are to the quarter ended June ... Quarter 2017 Highlights include: Revenue of ... Total prescriptions dispensed of 220,000, compared to ... Gross profit per prescription dispensed of ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... Any Lab Test ... The company ranked #4429 on the newly released, 36th annual Inc. 5000 , ... unique look at the most successful companies within the American economy’s most dynamic segment ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... of their recently launched community enrichment program. Partnering once again with Boys & ... Superstar competition to help find the area’s very own American Idol. With all ...
(Date:8/16/2017)... PA (PRWEB) , ... August 16, 2017 , ... A ... it has successfully opened clubfoot clinics in all 29 Indian states—bringing the country one ... clinic in Kangra, Himachal Pradesh, the nonprofit organization is on track to enroll 10,000 ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... company based in Vero Beach, announced today that two of their associates were ... that represents professionally managed senior living communities in Florida. The awards were announced ...
(Date:8/16/2017)... ... August 16, 2017 , ... The ... men and women to train as hospice volunteers. Volunteers provide much needed joy, ... over 30 years, the agency has trained volunteers to be vital members of ...
Breaking Medicine News(10 mins):